← Leaderboards
Jason R. McCarthy
Massachusetts General Hospital
$8,263,208
Attributed
$11,640,318
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,640,318 · 8
By mechanism
R01$8,138,710 · 3
R21$1,793,409 · 4
U01$1,708,199 · 1
Top collaborators
- Carl Atkinson4 shared
- Jonathan Schoenecker4 shared
- Benjamin D Medoff3 shared
- Donald R. Menick2 shared
- Andrew M Tager1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Michael R Hamblin$6,140,037
- Purushothama Rao Tata$8,032,646
- Ralph Weissleder$110,468,710
- Tayyaba Hasan$21,611,486
- J Manuel Perez$2,482,363
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignCellsNanoparticleResponseDoseIn VitroPathway InteractionsCell TypeNanomaterialsIn VivoInflammatoryMediatingEndothelial CellsPharmaceutical PreparationsUptakeCollagenPeptidesEnvironmentMonocyteBasePreventionImmunosuppressive AgentsLigandsMacrophage
Grant awards (23)
Biomimetic nanomaterials for the immunomodulation of the cardiosplenic axis post-myocardial infarction$729,140
R01 · FY2025 · HL
Targeted delivery of immunosuppressive agents to the graft endothelium forthe prevention of rejection in lung transplantation$434,685
U01 · FY2025 · AI
Biomimetic nanomaterials for the immunomodulation of the cardiosplenic axis post-myocardial infarction$741,890
R01 · FY2024 · HL
Targeted delivery of immunosuppressive agents to the graft endothelium forthe prevention of rejection in lung transplantation$449,683
U01 · FY2024 · AI
Splenic Modulation of SHP-2 Activity as a Therapeutic Option for Systemic Lupus Erythematosus$189,926
R21 · FY2024 · AR · contact PI
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation$405,353
U01 · FY2023 · AI
Splenic Modulation of SHP-2 Activity as a Therapeutic Option for Systemic Lupus Erythematosus$234,960
R21 · FY2023 · AR · contact PI
Mechanistic insights into polyphosphate-mediated osteoinduction.$193,050
R21 · FY2023 · AR · contact PI
An inorganic polyphosphate-impregnated synthetic periosteum drives allograft osteointegration$191,854
R21 · FY2023 · AR
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation$418,478
U01 · FY2022 · AI
Mechanistic insights into polyphosphate-mediated osteoinduction.$251,270
R21 · FY2022 · AR · contact PI
An inorganic polyphosphate-impregnated synthetic periosteum drives allograft osteointegration$245,974
R21 · FY2022 · AR
Targeted inhibition of fibrosis for the prevention of heart failure$797,039
R01 · FY2019 · HL · contact PI
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary Fibrosis$673,211
R01 · FY2019 · HL
Targeted inhibition of fibrosis for the prevention of heart failure$797,333
R01 · FY2018 · HL · contact PI
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary Fibrosis$673,211
R01 · FY2018 · HL
Targeted inhibition of fibrosis for the prevention of heart failure$789,681
R01 · FY2017 · HL · contact PI
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary Fibrosis$673,211
R01 · FY2017 · HL · contact PI
Targeted inhibition of fibrosis for the prevention of heart failure$786,135
R01 · FY2016 · HL · contact PI
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary Fibrosis$673,211
R01 · FY2016 · HL
Targeted inhibition of fibrosis for the prevention of heart failure$804,648
R01 · FY2015 · HL · contact PI
Multimodal nanoagents for the detection and treatment of atherosclerosis$221,250
R21 · FY2010 · HL · contact PI
Multimodal nanoagents for the detection and treatment of atherosclerosis$265,125
R21 · FY2009 · HL · contact PI